19 results about "Axon growth" patented technology

The invention relates to the technical field of biomedical materials, in particular to a high-conductivity peripheral nerve socketed pipe and a preparation method thereof. The nerve socketed pipe is a hollow cylindrical socketed pipe made of a material containing poly (octylene-citrate-co-octanol) POCO, and a regeneration promoting material is loaded in the hollow cylindrical socketed pipe; the regeneration promoting material comprises fetal calf serum and a DMEM cell culture medium. The POCO has the advantages of conductive activity, nerve regeneration induction, free radical scavenging ability, oxidation resistance, deformation resistance and the like, and has good degradability and biocompatibility, so that the nerve socketed pipe is prepared from poly (octylene-citrate-co-octanol), and the growth of axons is accelerated through electrical stimulation. Furthermore, at least one conductive monomer of pyrrole, aniline, p-phenylenediamine, o-methoxyaniline, thiophene, 3-hexylthiophene, 3-thiopheneacetic acid and 3, 4-ethylenedioxythiophene is adopted for modifying the POCO hollow cylindrical socketed pipe through in-situ oxidative polymerization, and the performance of the POCO hollow cylindrical socketed pipe serving as the neural restoration material is further improved.

The invention discloses an application of a CDKN1A interaction zinc finger protein 1 in neuronal axon regulation and control. The invention proposes and verifies that the CDKN1A interaction zinc finger protein 1 can effectively regulate and control the growth behavior of neuron axons for the first time, the growth of the neuron axons and the regeneration of damaged axons can be promoted by inhibiting the expression of the CDKN1A interaction zinc finger protein 1, and a new direction is provided for research and development of drugs for treating diseases caused by neurodegenerative diseases and nerve injuries.

The application provides application of guanine and isoguanine in preparation of drugs for treating or repairing peripheral nerve injury, and relates to the technical field of biomedicine, and the technical scheme is characterized in that the application provides application of guanine Guanine and / or isoguanine Isoguanine in preparation of drugs for treating or repairing peripheral nerve injury.In the application, it is verified through specific examples that adding guanine and isoguanine in resuspended DRG neurons in vitro can significantly promote the growth of DRG neuron axons, and in the application, guanine and isoguanine can regulate DRG neuron cell axon growth in the process of peripheral nerve injury and regeneration, which helps better understand the important role of Guanine and Isoguanine in the process of nerve injury repair, and meanwhile, the effectiveness of the drugs for repairing or treating peripheral nerve injury is verified; and a new target point is provided for treatment of related nervous system diseases.

The invention discloses application of a deubiquitinating enzyme inhibitor and an OTUD7A-HINT1-mTOR axis in regeneration of a central nervous system, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to promote the regeneration of the central nervous system. The invention finds that the deubiquitinating enzyme inhibitor PR-619 can promote the growth of axons in neuron cultures and retina explants, protect the survival of RGCs and enhance the regeneration of axons after ONC. The PR-619 can also promote CNS regeneration by down-regulating expression of HINT1, HINT is one of main targets of the PR-619 and plays a role through an mTOR signal channel, and OTUD7A serves as an upstream regulation factor of the HINT1. The PR-619 can be used for treating the CNS injury, the OTUD7A-HINT1-mTOR axis can be used as a CNS injury treatment target, and the PR-619 and the OTUD7A-HINT1-mTOR axis can be combined for treating the CNS injury.

Preparation method and application of diterpenoid, relate to the application technical field of diterpenoid.The present application separates two new compounds of diterpenoid A and diterpenoid B from a strain of Hericium fermentation extract, and discloses chemical structural formula of the two compounds, and corresponding nuclear magnetic, mass spectrum, infrared and ultraviolet data, and its function of significantly inhibiting the production of inflammatory BV2 cell NO.Diterpenoid B has 24% of the promotion rate of axon growth of PC-12 cell, and simultaneously has significant inhibition of TLR4 / NF-κB signal path to inhibit downstream inflammatory proteins of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and diterpenoid A and diterpenoid B both show significant anti-neuroinflammatory activity.The present application can obtain the preparation method and application of diterpenoid.

The present invention relates to use of slow-releasing hydrogen sulfide organic donor ADT-OH drugs in the differentiation of neural precursor cells. ADT-OH can induce more directed differentiation of neural precursor cells into neurons and oligodendrocytes and less differentiation into astrocytes, promote the axon growth of neurons, and reduce the death of neural precursor cells, thereby providing a direction for the transplantation of neural precursor cells to repair damaged nerves. ADT-OH will likely become a new drug target for the clinical treatment of nervous system diseases.

The application discloses a nerve regeneration guide conduit for promoting nerve cell differentiation and a preparation method and application thereof. The nerve regeneration guide conduit can realize stable and long-acting release of bioactive factors, effectively reduce the risk of tissue adhesion, efficiently induce nerve cell differentiation, promote axon growth and function recovery, and provides a novel and effective solution for nerve regeneration and repair. In addition, the nerve regeneration guide conduit has excellent conductivity, biocompatibility, mechanical adaptability and the like, and therefore has a wide application prospect in the field of nerve regeneration and repair.

The invention relates to a neural stem cell-parathymosin composite cell preparation and application thereof in treatment of nerve injury diseases. According to the invention, it is found for the first time that neural stem cells overexpressing parathymosin (PTMS) can effectively promote neuron neogenesis and axon growth in in-vitro and in-vivo experiments; animal experiment results show that the traditional Chinese medicine composition can also be used as a treatment means for promoting nerve regeneration to resist dyskinesia related to nerve injury diseases.

The invention provides application of Syn3 in preparation of medicines for treating spinal cord injury, and belongs to the technical field of biological medicines. The invention finds that the PSD95 binding peptide Syn3 can promote coupling of rkB-PSD95-G alphai1 / 3 signal compounds, promote a BDNF-TrkB downstream PI3K-Akt signal channel and play a role in promoting neuronal axon growth, meanwhile, the Syn3 can penetrate through a blood spinal cord barrier to reach a spinal cord part and be stably combined with PSD95, after in-vivo injection, growth cone depolymerization and axon regeneration after spinal cord injury can be promoted, a neural circuit is further reconstructed, and the effect of promoting neuronal axon growth is achieved. Motion functions and nerve electrophysiology of the hind limbs of the mouse are recovered.

The invention relates to the technical field of microbial medicines, and particularly discloses application of intestinal golden thread bacteria in preparation of a medicine for preventing or treating peripheral nerve injury. A mouse model proves that the intestinal golden thread bacteria can regulate the injury microenvironment in the peripheral nerve injury repair process, guide nerve axons to extend in the expected direction and reduce uncontrolled axon growth and wrong dominance, so that the structural accuracy of nerve regeneration is improved.

The invention relates to the technical field of medical equipment, and discloses an electrical stimulation device for axon regeneration and a control method. The electrical stimulation device comprises a control assembly used for generating an electrical signal and transmitting the electrical signal to a stimulation electrode; the stimulation electrodes are connected with the control assembly and are used for being placed on the two sides of a nerve injury plane respectively, so that an electric field is formed in the axon growth direction based on the electric signals, and axons are stimulated to grow across the nerve injury plane; the axon growth stimulation method is simple, and the cost is controllable; and the direction of the electric field is matched with the growth direction of the axons, so that the problem of disorder of a nerve regeneration network caused by random growth of the axons possibly caused by a traditional treatment method can be avoided, and the axon growth effect is improved.

The invention discloses application of the M2 type microglial cell exosome. The invention discloses an application of an M2 type microglial cell exosome in preparation of a product for treating diabetic retina neuropathy. In combination with a specific embodiment, the M2 type microglial cell exosome (M2-Exos) is separated and proved to promote the survival and axon growth of primary RGCs in vitro. In an STZ-induced diabetic mouse model, in-vivo injection of M2-Exos prevents RGC loss by inhibiting a pro-inflammatory mediator and enhancing an anti-inflammatory factor, so that ganglion cell complex thickness and visual ability are retained. The axon regeneration promoting ability of the M2-Exos is further verified in an optic nerve crushing animal model. The discovery shows that the M2-Exos is a potential neuroprotection and axonal regeneration promotion tool for treating the diabetic retina neuropathy, and the M2-Exos can be used for preparing products for treating the diabetic retina neuropathy.

The invention discloses a Wipi1 gene inhibitor and an application thereof. The Wipi1 gene inhibitor comprises siRNA used for inhibiting Wipi1 gene expression, and the Wipi1 gene inhibitor can be applied to preparation of drugs for repairing nerve injury or drugs for promoting neuronal axon growth. The neuronal axon growth is promoted by down-regulating the expression quantity of the Wipi1 gene in the neurons, and the neuronal axon growth is regulated in vitro by taking the Wipi1 gene as a target spot. According to the invention, the Wipi1 gene is used as a regulation target to regulate the regeneration of neuronal axons after peripheral and central nervous injury; regeneration and repair after neuronal axon injury are promoted by down-regulating expression of the Wipi1 gene, a brand new regulation target is provided for treatment of neuronal axon injury, and development of new treatment means and strategies is facilitated.

The present disclosure provides a method of treating or ameliorating a disease or disorder comprising administering to a subject a crystalline form of a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. The disclosure further provides a method of stimulating neurogenesis or neurite growth resulting in an increase in neuronal length.

Deacetylation of rat Miro1 on Lysine 105 attenuates axon growth on nonpermissive substrates by making mitochondria more sensitive to Ca levels, depolarizing mitochondrial membranes and blocking mitochondrial transport; the current disclosure provides an antibody that specifically recognizes the lysine 105 acetylated and not the deacetylated Miro1 protein.

The application discloses application of an ACSS2 gene in preparation of a medicine for treating or repairing nerve injury, and belongs to the technical field of biological medicines. The application finds, through transcriptome sequencing results of spinal cord injury and sciatic nerve pinch injury, that the expression of ACSS2 presents a gradually decreasing trend after spinal cord injury and sciatic nerve pinch injury, and then the application adopts an adeno-associated virus to overexpress ACSS2 in neuron primary cells, and the result shows that the length of neuron axons is significantly increased after overexpression of ACSS2. Therefore, a substance for promoting the expression of the ACSS2 gene can realize treatment or repair of nerve injury by promoting the growth of neuron axons.

A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they also show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

This invention discloses a neurofilament light chain protein derivative, biomaterial, and its applications. The neurofilament light chain protein derivative is a protein based on the neurofilament light chain protein or its homologous protein with the sequence shown in SEQ ID NO: 1, wherein one or more amino acid residues in the Coil 2B region have pharmaceutically acceptable modifications or mutations. This invention designs and constructs a neurofilament light chain protein K316Q mutant by acetylation-mimicking mutation of the neurofilament light chain protein, which exhibits significant effects in promoting nerve growth and regeneration. This mutant can enhance the stability and function of neurofilament networks, promote the expansion of axonal growth cones, and directly target the intrinsic growth capacity of neurons, demonstrating excellent clinical translational potential.